Affimed (AFMD) to Release Quarterly Earnings on Thursday

Affimed (NASDAQ:AFMD) is set to post its quarterly earnings results before the market opens on Thursday, September 5th. Analysts expect Affimed to post earnings of ($1.00) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Affimed (NASDAQ:AFMD) last released its quarterly earnings results on Wednesday, June 12th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.73) by $0.35. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.76 million. Affimed had a negative net margin of 2,361.94% and a negative return on equity of 135.81%. On average, analysts expect Affimed to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Affimed Price Performance

Shares of NASDAQ:AFMD opened at $3.95 on Wednesday. Affimed has a 1 year low of $2.23 and a 1 year high of $8.95. The firm has a fifty day moving average price of $4.74 and a 200 day moving average price of $5.28. The company has a current ratio of 3.06, a quick ratio of 3.06 and a debt-to-equity ratio of 0.12.

Analyst Upgrades and Downgrades

AFMD has been the topic of a number of recent analyst reports. Laidlaw raised their price objective on Affimed from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Affimed in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.